Abstract

Huntington disease is a neurodegenerative condition for which there is no cure to date. Activation of AMP-activated protein kinase has previously been shown to be beneficial in in vitro and in vivo models of Huntington’s disease. Moreover, a recent cross-sectional study demonstrated that treatment with metformin, a well-known activator of this enzyme, is associated with better cognitive scores in patients with this disease. We performed a preclinical study using metformin to treat phenotypes of the zQ175 mouse model of Huntington disease. We evaluated behavior (motor and neuropsychiatric function) and molecular phenotypes (aggregation of mutant huntingtin, levels of brain-derived neurotrophic factor, neuronal inflammation, etc.). We also used two models of polyglutamine toxicity in Caenorhabditis elegans to further explore potential mechanisms of metformin action. Our results provide strong evidence that metformin alleviates motor and neuropsychiatric phenotypes in zQ175 mice. Moreover, metformin intake reduces the number of nuclear aggregates of mutant huntingtin in the striatum. The expression of brain-derived neurotrophic factor, which is reduced in mutant animals, is partially restored in metformin-treated mice, and glial activation in mutant mice is reduced in metformin-treated animals. In addition, using worm models of polyglutamine toxicity, we demonstrate that metformin reduces polyglutamine aggregates and restores neuronal function through mechanisms involving AMP-activated protein kinase and lysosomal function. Our data indicate that metformin alleviates the progression of the disease and further supports AMP-activated protein kinase as a druggable target against Huntington’s disease.

Huntington’s disease: Diabetes drug limits disease-related degeneration in mice

Metformin, an existing drug for diabetes, shows promise in alleviating symptoms of early Huntington’s disease in mouse models. Huntington’s disease is a genetic disorder that results in the gradual deterioration of motor skills and cognitive ability. It is caused by a defect in a single gene that then encodes a mutant huntingtin protein, which aggregates and kills brain cells. Growing observational evidence suggests that patients undergoing metformin treatment for diabetes type II exhibit fewer symptoms of age-related disease, as well as Huntington’s disease. Rafael Vázquez-Manrique at Hospital Universitario y Politécnico La Fe, València and Pascual Sanz at IBV-CSIC and CIBERER, València, and scientists across Spain used metformin to treat motor and neuropsychiatric symptoms in a Huntington’s mouse model. They found that metformin alleviated symptoms by actively reducing huntingtin levels, dispersing aggregations and limiting brain inflammation.

Details

Title
Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease
Author
Sanchis, Ana 1 ; García-Gimeno, María Adelaida 2 ; Cañada-Martínez, Antonio José 3   VIAFID ORCID Logo  ; Sequedo, María Dolores 4 ; Millán, José María 4 ; Sanz Pascual 5 ; Vázquez-Manrique, Rafael P 4   VIAFID ORCID Logo 

 Health Research Institute La Fe (Hospital Universitario y Politécnico La Fe), Research Group in Molecular, Cellular and Genomic Biomedicine, València, Spain (GRID:grid.84393.35) (ISNI:0000 0001 0360 9602) 
 Universitat Politécnica de València, Department of Biotechnology, Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural (ETSIAMN), València, Spain (GRID:grid.157927.f) (ISNI:0000 0004 1770 5832) 
 Health Research Institute La Fe (Hospital Universitario y Politécnico La Fe), Statistics Unit, València, Spain (GRID:grid.84393.35) (ISNI:0000 0001 0360 9602) 
 Health Research Institute La Fe (Hospital Universitario y Politécnico La Fe), Research Group in Molecular, Cellular and Genomic Biomedicine, València, Spain (GRID:grid.84393.35) (ISNI:0000 0001 0360 9602); CIBER de Enfermedades Raras (CIBERER), Madrid, Spain (GRID:grid.452372.5) (ISNI:0000 0004 1791 1185) 
 CIBER de Enfermedades Raras (CIBERER), Madrid, Spain (GRID:grid.452372.5) (ISNI:0000 0004 1791 1185); CSIC, Instituto de Biomedicina de València, València, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846) 
Pages
1-16
Publication year
2019
Publication date
Jun 2019
Publisher
Springer Nature B.V.
ISSN
12263613
e-ISSN
20926413
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2235651267
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.